118684-32-5

Usage

Uses

Used in Pharmaceutical Synthesis:
Tert-Butyl 3-(bromomethyl)phenylcarbamate is used as an intermediate in the synthesis of pharmaceuticals for its ability to introduce the bromomethyl functional group, which is crucial for the development of new drugs with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, tert-Butyl 3-(bromomethyl)phenylcarbamate is used as a reagent to incorporate the bromomethyl functional group into various organic molecules, enhancing their chemical properties and potential applications.
Used in Agricultural Chemical Production:
Tert-Butyl 3-(bromomethyl)phenylcarbamate is employed in the production of agricultural chemicals, where its unique functional group contributes to the development of effective and targeted agrochemicals for crop protection and enhancement.
Used in Material Science:
In the realm of material science, tert-Butyl 3-(bromomethyl)phenylcarbamate is utilized in the development of new materials, leveraging its chemical properties to create innovative and improved materials for various applications.
Used in Research and Development:
Tert-Butyl 3-(bromomethyl)phenylcarbamate is used as a research compound in the exploration of new chemical reactions and the discovery of novel applications, further expanding its utility in the scientific community.

Upstream product

• 1877-77-6 3-aminobenzenemethanol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 118684-31-4 tert-butyl N-[3-(hydroxymethyl)phenyl]carbamate 

Downstream Products

• 211761-53-4 [3-(3-azido-7-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-ylmethyl)-phenyl]-carbamic acid tert-butyl ester 
• 299217-20-2 3-(3'-N-BOC-aminobenzyloxy)-5-hydroxybenzyl alcohol 
• 1402397-26-5 C₃₃H₅₁N₅O₄S 
• 1476778-29-6 C₂₀H₂₂N₄O₂ 
• 1476778-31-0 C₂₄H₂₂N₄O₃ 
• 1476778-30-9 C₁₅H₁₄N₄ 
• 1476778-32-1 C₂₂H₁₈N₄O₃*BrH 

Relevant academic research and scientific papers

Adenosine receptor antagonists

The invention provides a compound shown as a formula (I) and a pharmaceutical composition thereof. The compounds of formula (I) of the present invention are useful as adenosine receptor inhibitors, especially A2A and/or A2B inhibitors, for example, the product can be used for prevention or treatment of diseases associated with A2A and/or A2B activity or expression.

GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.

N-alkyl ammonia methylaniline and synthetic, and is used for its polymer anti-corrosion metal surface

The invention discloses N-alkyl aminomethyl aniline as well as synthesis and a polymer thereof and application of the N-alkyl aminomethyl aniline in metal surface anticorrosion. According to the characteristics that after the amine corrosion inhibitor is

QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS

Compounds of formula (Ι') that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

A tetrameric hetero-octanuclear cyclic helicate formed from a bridging ligand with two inequivalent binding sites

A bis-bidentate bridging ligand H2L with inequivalent hard and soft binding sites (catecholate and pyrazolyl-pyridine, respectively) reacts with a mixture of Ti(iv) and Zn(ii) ions to afford an octanuclear heterometallic Ti4Zn4

SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF

This invention provides compounds of formula (I): wherein R1a, R1b, Ra, R2a, R2b, R1, and X have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.

Cyclization of synthetic seco-proansamitocins to ansamitocin macrolactams by actinosynnema pretiosum as biocatalyst

Ring closure is possible with seco-proansamitocin and two activated SNAC esters, which can be processed to ansamitocin P3 and 19-deschloro-20-demethoxy AP-3, respectively, by an AHBA-blocked mutant of Actinosynnema pretiosum. This work sheds light on the

Pyrazole glucokinase activators

Disclosed herein are pyrazole glucokinase activators of the formula (I) useful for the treatment of metabolic diseases and disorders, preferably diabetes mellitus.

Substituted cyclic compounds and mixtures comprising same

Novel chemical compounds and mixtures of same are provided having antibacterial and other utilities. The mixtures preferably are formed by reacting a cyclic scaffold moiety with a set of chemical substituients. Libraries formed in accordance with the inve

Dendroid peptide structural mimetics of ω-conotoxin MVIIA based on a 2(1H)-quinolinone core

Three mimetics of the peptide ω-Conotoxin MVIIA have been synthesised following the dendroid approach. The three key central amino acids of the natural peptide are mimicked by phenylguanidine (arginine), isopentyl (leucine) and aryl alcohol (tyrosine) att